(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA), the trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, released the following statement today following the passage of H.R. 2430, the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. House of Representatives.
“CHPA congratulates the House of Representatives and House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), Ranking Member Frank Pallone (D-N.J.), Health Subcommittee Chairman Michael Burgess (R-Texas), and Health Subcommittee Ranking Member Gene Green (D-Texas) on the passage of the Food and Drug Administration Reauthorization Act of 2017. While OTC Monograph reform (OMUFA) was not included in the House FDARA legislation, CHPA has been, and continues to be, encouraged by the bipartisan momentum we’ve seen behind Monograph reform in both the House and Senate.
“We remain confident that OTC Monograph reform will continue to be on the agenda this Congress and appreciate our House and Senate champions’ advocacy for the legislation. Modernization of the OTC Monograph system is something FDA, industry, and public health stakeholders agree is necessary to spur innovation as well as increase the efficiency and responsiveness necessary to protect consumer health.”
